Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/12/2018
SIETES contiene 92610 citas

 
 
 1 a 20 de 167 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Akturk HK, Taylor DD, Camsari UM, Rewers A, Kinney GL, Shah VN. Association between cannabis use and risk for diabetic ketoacidosis in adults with type 1 diabetes. JAMA Intern Med 2018:5 de noviembre. [Ref.ID 102851]
2. Cita con resumen
Campaigno EP, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-induced dental caries: a disproportionality analysis using data from VigiBase. Drug Saf 2017;40:1249-58. [Ref.ID 102146]
3. Cita con resumen
Laatikainen O, Mietttunen J, Sneck S, Lehtiniemi H, Tenhunen O, Turpeinen M. The prevalence of medication-related adverse events in inpatients-a systematic review and meta-analysis. Eur J Clin Pharmacol 2017;73:1539-49. [Ref.ID 102145]
4. Cita con resumen
Hu Y-m, Zhou F, Yuan Y, Xu Y-c. Efectos del suplemento de probióticos en pacientes con diabetes tipus 2: mataanálisis de ensayos aleatorizados. Med Clin (Barc) 2017;148:362-70. [Ref.ID 101575]
5.Tiene citas relacionadas Cita con resumen
Messerli FH, Bangalore S, Grossman E. Adverse effects and tolerability of ß blockers. BMJ 2016;353:i3142. [Ref.ID 100378]
7. Cita con resumen
Fathallah N, Slim R, Larif S, Hmouda H, Ben Salem C. Drug-induced hyperglycaemia and diabetes. Drug Saf 2015;38:1153-68. [Ref.ID 99783]
8. Cita con resumen
Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, Castagneto M, Bornstein S, Rubino F. Bariatric–metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-73. [Ref.ID 99528]
9. Cita con resumen
Warlé-van Herwaarden MF, Valkhoff VE, Herings RMC, Engelkes M, van Blijderveen JC, Rodenburg EM, de Bie S, Alsma J, van de Steeg-Gompel C, Kramers C, Meyboom RHB, Sturkenboom MCJM, De Smet PAGM. Quick assessment of drug-related admissions over time (QUADRAT study). Pharmacoepidemiol Drug Saf 2015;24:495-503. [Ref.ID 98885]
10. Cita con resumen
Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf 2014;37:791-804. [Ref.ID 98404]
11. Cita con resumen
Jenkins DJA, Kendall CWC, Vuksan V, Faulkner D, Augustin LSA, Mitchell S, Ireland C, Srichaikul K, Mirrahimi A, Chiavaroli L, Mejia SB, Nishi S, Sahye-Pudaruth S, Patel D, Bashyam B, Vidgen E, de Souza RJ, Sievenpiper JL, Coveney J, Josse RG, Leiter LA. Effect of lowering the glycemic load with canola oil on glycemic control and cardiovascular risk factors: a randomized controlled trial. Diabetes Care 2014;37:1806-14. [Ref.ID 97658]
12. Cita con resumen
Geller AI, Shehab N, Lovegrove MC, Kegler SR, Weidenbach KN, Ryan GJ, Budnitz DS. National estimates of insulin-related hypoglycemia and errors leading to emergency department visits and hospitalizations. JAMA Intern Med 2014;174:678-86. [Ref.ID 97300]
13. Cita con resumen
Anónimo. Statins and diabetes risk. Med Lett Drugs Ther 2014;56:79-80. [Ref.ID 97038]
14.Tiene citas relacionadas
Shlipak MG, Coresh J, Gansevoort RT. Cystatin C versus creatinine for kidney function-based risk. The authors reply. N Engl J Med 2013;369:2459. [Ref.ID 96682]
15.Tiene citas relacionadas
Vandecasteele SJ, De Vriese AS. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458-9. [Ref.ID 96681]
16.Tiene citas relacionadas Cita con resumen
Cherney D, Maahs DM. Cystatin C versus creatinine for kidney function-based risk. N Engl J Med 2013;369:2458. [Ref.ID 96680]
17. Cita con resumen
Engebretson SP, Hyman LG, Michalowicz BS, Schoenfeld ER, Gelato MC, Hou W, Sequist ER, Reddy MS, Lewis CE, Oates TW, Tripathy D, Katancik JA, Orlander PR, Paquette DW, Hanson NQ, Tsai MY. The effect of nonsurgical periodontal therapy on hemoglobin A1c levels in persons with type 2 diabetes and chronic periodontitis: a randomized clinical trial. JAMA 2013;310:2523-32. [Ref.ID 96673]
18. Cita con resumen
Kuehn BM. FDA warning and study highlight fluoroquinolone risks. JAMA 2013;310:1014. [Ref.ID 96081]
19. Cita con resumen
Chou H-W, Wang J-L, Chang C-H, Lee J-J, Sau W-Y, Lai MS. Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan. Clin Infect Dis 2013;57:971-80. [Ref.ID 95903]
20. Cita con resumen
Slomski A. Avoiding hypoglycemia at all costs is crucial for some with diabetes. JAMA 2013;309:2536-7. [Ref.ID 95732]
Seleccionar todas
 
 1 a 20 de 167 siguiente >>